Organization
Virogin Biotech, Coquitlam, BC, Canada
1 abstract
Abstract
The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Banner MD Anderson Cancer Center, Gilbert, AZ, Virogin Biotech, Jonesville, FL, Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Virogin Biotech (Shanghai) Ltd, Shanghai, China,